Different classes of topoisomerase (TOP) inhibitors and antitrypanosomatid agents exhibited
variable efficacies against Leishmania donovani parasites and human mononuclear cells …

Objectives: Investigation of the antiproliferative synergy of the lysophospholipid analogues
(LPAs) edelfosine, ilmofosine and miltefosine with the ergosterol biosynthesis inhibitor …

Leishmaniasis chemotherapy is a bottleneck in disease treatment. Although available,
chemotherapy is limited, toxic, painful, and does not lead to parasite clearance, with parasite …

The protozoan parasite Leishmania causes a spectrum of diseases and there are over 1
million infections each year. Current treatments are toxic, expensive, and difficult to …

We describe here the effects of Δ24 (25) sterol methenyl transferase inhibitors (SMTI) on
promastigote and axenic amastigote forms of Leishmania amazonensis. When these cells …

Miltefosine is the only oral drug approved for the treatment of various clinical presentations
of the neglected parasitic disease leishmaniasis. In cutaneous leishmaniasis and post-kala …

The leishmaniases consist of visceral and cutaneous syndromes present in> 30 endemic
regions of the world. Miltefosine (hexadecylephosphocholine) is the first oral agent that is …

Abstract Cryptolepine (5-methyl-10 H-indolo [3, 2-b] quinoline), an indoloquinoline alkaloid
(1) isolated from a medicinal plant traditionally used in Western Africa for treatment of …

Abstract Quinoline and 1, 2, 3-triazoles are well-known nitrogen-based heterocycles
presenting diverse pharmacological properties, although their antileishmanial activity is still …

Miltefosine is an alkylphosphocholine that shows broad-spectrum in vitro antifungal activities
and limited in vivo efficacy in mouse models of cryptococcosis. To further explore the …